Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2018 | Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial | Ridker P.M.; MacFadyen J.G.; Everett B.M.; Libby P.; Thuren T.; Glynn R.J.; Kastelein J.; Koenig W.; Genest J.; Lorenzatti A.; Varigos J.; Siostrzonek P.; Sinnaeve P.; Fonseca F.; Nicolau J.; Gotcheva N.; Yong H.; Urina-Triana M.; Milicic D.; Cifkova R.; Vettus R.; Anker S.D.; Manolis A.J.; Wyss F.; Forster T.; Sigurdsson A.; Pais P.; Fucili A.; Ogawa H.; Shimokawa H.; Veze I.; Petrauskiene B.; Salvador L.; Cornel J.H.; Klemsdal T.O.; Medina F.; Budaj A.; Vida-Simiti L.; Kobalava Z.; Otasevic P.; Pella D.; Lainscak M.; Seung K.-B.; Commerford P.; Dellborg M.; Donath M.; HWANG, JUEY-JEN ; Kultursay H.; Flather M.; Ballantyne C.; Bilazarian S.; Chang W.; East C.; Forgosh L.; Harris B.; Ligueros M.; CANTOS Trial Group | The Lancet | 606 | 515 |